506 related articles for article (PubMed ID: 25156366)
1. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
2. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
[TBL] [Abstract][Full Text] [Related]
3. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
[TBL] [Abstract][Full Text] [Related]
4. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
5. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
6. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
7. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
8. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
[TBL] [Abstract][Full Text] [Related]
9. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.
Sohn SJ; Barrett K; Van Abbema A; Chang C; Kohli PB; Kanda H; Smith J; Lai Y; Zhou A; Zhang B; Yang W; Williams K; Macleod C; Hurley CA; Kulagowski JJ; Lewin-Koh N; Dengler HS; Johnson AR; Ghilardi N; Zak M; Liang J; Blair WS; Magnuson S; Wu LC
J Immunol; 2013 Sep; 191(5):2205-16. PubMed ID: 23894201
[TBL] [Abstract][Full Text] [Related]
10. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk.
Tortola L; Rosenwald E; Abel B; Blumberg H; Schäfer M; Coyle AJ; Renauld JC; Werner S; Kisielow J; Kopf M
J Clin Invest; 2012 Nov; 122(11):3965-76. PubMed ID: 23064362
[TBL] [Abstract][Full Text] [Related]
11. Ginsenoside Rg1 abolish imiquimod-induced psoriasis-like dermatitis in BALB/c mice via downregulating NF-κB signaling pathway.
Shi Q; He Q; Chen W; Long J; Zhang B
J Food Biochem; 2019 Nov; 43(11):e13032. PubMed ID: 31502279
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of JAK1/STAT3 pathway by 2-methoxyestradiol ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like mouse model.
Tang J; Liu C; Liu S; Zhou X; Lu J; Li M; Zhu L
Eur J Pharmacol; 2022 Oct; 933():175276. PubMed ID: 36130639
[TBL] [Abstract][Full Text] [Related]
13. A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor.
Menet CJ
J Med Chem; 2018 Oct; 61(19):8594-8596. PubMed ID: 30252456
[No Abstract] [Full Text] [Related]
14. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
15. Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis.
Takahashi T; Koga Y; Kainoh M
Eur J Pharmacol; 2018 Jun; 828():26-30. PubMed ID: 29544684
[TBL] [Abstract][Full Text] [Related]
16. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
[TBL] [Abstract][Full Text] [Related]
17. MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice.
OuYang Q; Pan Y; Luo H; Xuan C; Liu J; Liu J
Int Immunopharmacol; 2016 Oct; 39():369-376. PubMed ID: 27540765
[TBL] [Abstract][Full Text] [Related]
18. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
19. TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.
Gracey E; Hromadová D; Lim M; Qaiyum Z; Zeng M; Yao Y; Srinath A; Baglaenko Y; Yeremenko N; Westlin W; Masse C; Müller M; Strobl B; Miao W; Inman RD
J Clin Invest; 2020 Apr; 130(4):1863-1878. PubMed ID: 32149730
[TBL] [Abstract][Full Text] [Related]
20. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
